Endo International Plc (ENDP) confirms it is withdrawing its cash-and-stock offer to acquire Salix Pharma (SLXP) following Valeant Pharmaceuticals’ (VRX) revised offer of $11.1 billion in cash. “While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions. We would like to wish Salix […] View the full post at: Endo (ENDP) Withdraws Salix (SLXP) Proposal Related posts: GM Bondholder Statement on the Debt for Equity Swap Proposal NY Empire State Manufacturing: “Highest Since August” After-Hours and Pre-Market Earnings (Oct. 28)